表柔比星联合紫杉醇的新辅助化疗治疗三阴性乳腺癌的效果  

Effect of Neoadjuvant Chemotherapy with Epirubicin Combined with Paclitaxel in the Treatment of Triple Negative Breast Cancer

作　　者：冯辉 FENG Hui(Department of Oncology,Xingcheng People's Hospital,Xingcheng 125100,China)

机构地区：[1]兴城市人民医院肿瘤科,辽宁兴城125100

出　　处：《中国医药指南》2020年第34期81-82,共2页Guide of China Medicine

摘　　要：目的探讨表柔比星联合紫杉醇的新辅助化疗治疗三阴性乳腺癌的临床效果。方法选取2018年1月至2019年1月我院收治的三阴性乳腺癌病患78例,利用随机数字表法分为单药组及联合组,各39例,单药组使用表柔比星进行治疗,联合组在单药组治疗基础上应用联合紫杉醇的新辅助化疗方法进行治疗,比较两组病患的临床治疗效果、不良反应发生情况、健康状况及对治疗的耐受能力。结果联合组病患临床治疗总有效率、卡氏功能状态量表(KPS)评分高于单药组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用表柔比星联合紫杉醇的新辅助化疗治疗三阴性乳腺癌病患可取得较好的治疗效果,无显著不良反应,用药安全可靠。Objective To investigate the clinical efficacy of epirubicin combined with paclitaxel neoadjuvant chemotherapy in the treatment of triple negative breast cancer.Methods A total of 78 patients with triple-negative breast cancer were treated in our hospital from January 2018 to January 2019.Random number table was used to complete the randomized grouping,39 patients in the single application group were treated with epirubicin,while 39 patients in the combined application group were treated with neoadjuvant chemotherapy combined with paclitaxel on the basis of the single application group.Clinical effi cacy,occurrence of adverse reactions,health status and tolerance to treatment were compared.Results The total eff ective rate of clinical treatment and the KPS score of patients in the combined application group were higher than those in the single application drug group,the diff erence was statistically signifi cant(P<0.05);the diff erence in the incidence of adverse reactions between the two groups was not statistically signifi cant(P>0.05).Conclusion Neoadjuvant chemotherapy with epirubicin combined with paclitaxel for triple-negative breast cancer patients can achieve better therapeutic eff ects without signifi cant adverse reactions,and the medication is safe and reliable.

关 键 词：三阴性乳腺癌 表柔比星 紫杉醇 新辅助化疗 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]